German drugmaker Bayer AG has demanded the withdrawal of the country's first compulsory licence given to Natco Pharma, arguing that a three-fourth reduction in the price of the anti-cancer drug by another Indian firm has made the permit redundant and its patent itself is vulnerable to being revoked. In March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original...

-The Hindu   Achieving universal health coverage through an equitable system is among the key goals of India's 12th Plan. Within the overall objective of creating an entitlement-based health care system, one of the challenges is access to medicines. The High Level Expert Group instituted by the Planning Commission on Universal Health Coverage underscores serious policy distortions and inefficiencies that stand in the way of making essential medicines accessible to all. A...

-The United Nations   The United Nations agency mandated to spearhead the global response to HIV/AIDS today welcomed the new license agreement between the Medicines Patent Pool and the pharmaceutical company Gilead Sciences to increase access to antiretroviral therapy in developing countries. The Joint UN Programme on HIV/AIDS (UNAIDS) said the agreement marks the first time a pharmaceutical company has signed an agreement with the Medicines Patent Pool, describing it as a turning...

While ‘data exclusivity’ clauses will not feature in the India-European Union free trade agreement (FTA), the threat posed by the impending deal to the world’s supply of cheap generic drugs is far from over. India’s commerce and industry minister Anand Sharma assured Michel Sidibe, chief of the United Nations joint programme on HIV and AIDS (UNAIDS) at a meeting this week that India would reject attempts by pharmaceutical giants to include...

New Delhi has done well to declare its intention to play a proactive role at the forthcoming Convention on Biological Diversity (CBD) at Nagoya (Japan) in October for thrashing out a legally binding pact on access to and benefit-sharing of biological resources. Being one of the world’s 12 mega biodiversity centres, India has substantial stakes in both preserving the biodiversity and capitalising on its commercial potential. Though the CBD, signed...